- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Transcode Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 31.03. | Transcode Therapeutics, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 5 | SEC Filings | ||
| 27.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | 124 | PR Newswire | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen | |
| 25.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | TransCode Therapeutics Announces $10M Stock And Warrant Offering | 1 | RTTNews | ||
| 24.03. | TransCode Therapeutics stock slides after announces to raise $10M securities offering | 5 | Seeking Alpha | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.03. | TransCode Therapeutics Stock Surges 85% | 15 | RTTNews | ||
| 21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 546 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
| 13.03. | TransCode Therapeutics Advances Phase I Trial Of RNA Cancer Therapy | 5 | RTTNews | ||
| 13.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial | 177 | PR Newswire | Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3
No significant... ► Artikel lesen | |
| 25.02. | TransCode Therapeutics, Inc. Announces Results of Special Meeting | 549 | PR Newswire | BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more... ► Artikel lesen | |
| 25.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 06.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial | 255 | PR Newswire | No significant safety or dose limiting toxicities reported
PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results
BOSTON, Feb.... ► Artikel lesen | |
| 24.01. | TransCode Therapeutics Shares Are Surging Today: What's Going On? | 15 | Benzinga.com | ||
| 07.01. | TransCode Therapeutics regains compliance with Nasdaq | 5 | Seeking Alpha | ||
| 20.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | 201 | PR Newswire | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
| 06.12.24 | Transcode Therapeutics, Inc. - S-1, General form for registration of securities | 11 | SEC Filings | ||
| 02.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.12.24 | Why TransCode Therapeutics (RNAZ) Stock Is Diving | 8 | Benzinga.com |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,55 | -1,67 % | BioNTech-Aktie: Das muss man wirklich wissen! | News von Trading-Treff.de BioNTech hat sich sehr stark in die neue Woche eingeklinkt. Das Unternehmen konnte ein Plus in Höhe von 2,6 % verzeichnen. Schon am Freitag war es an der US-Börse NASDAQ um... ► Artikel lesen | |
| QIAGEN | 35,980 | -1,91 % | Qiagen NV-Aktie gewinnt 1,38 Prozent (35,71 €) | An der Börse notiert die Aktie von Qiagen NV aktuell etwas fester. Das Papier kostete zuletzt 35,71 Euro. Ein Kursplus von 1,38 Prozent steht gegenwärtig für die Qiagen NV-Aktie zu Buche. Das Wertpapier... ► Artikel lesen | |
| NOVAVAX | 5,242 | -0,72 % | Novavax-Aktie -20%: Eine gute Kaufchance? | Aus dem Nichts ist die Novavax-Aktie (WKN: A2PKMZ) am Donnerstag um fast -20% auf 5,43 US$ abgestürzt. Was steckt hinter dieser Rutsche? Und bietet sich vielleicht jetzt eine gute Kaufchance? RFK Jr.... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,189 | -1,56 % | Palatin's Phase 2 Obesity Study Shows Encouraging Appetite Suppression Data, Stock Up In Pre-Market | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN), Thursday announced results from its BMT-801 Phase 2 obesity study, which evaluated the co-administration of melanocortin 4 receptor or... ► Artikel lesen | |
| BRAIN BIOTECH | 2,240 | -3,45 % | EQS-News: BRAIN Biotech AG: Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Hauptversammlung
Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG
18.03.2025 / 16:45 CET/CEST
Für... ► Artikel lesen | |
| ORGANOVO | 1,930 | -100,00 % | Organovo, Inc.: Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements | SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,510 | -1,95 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,320 | 0,00 % | COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer | 25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO... ► Artikel lesen | |
| GENMAB | 174,40 | +0,29 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
| XOMA ROYALTY | 17,900 | +1,70 % | XOMA schließt Verkauf von Kinnate-Vermögenswerten für bis zu 270 Millionen US-Dollar ab | ||
| T2 BIOSYSTEMS | 0,077 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,730 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort | Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-K, Annual Report | ||
| ORAGENICS | 0,180 | +4,65 % | Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress | SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,72 % bei einem Aktienkurs von 0,265 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.
